Montrium’s eTMF Connect Solution Used in Global Phase III PTSD Study
Montrium, a provider of cloud-based software solutions for the life sciences, announced its eTMF Connect trial master file solution is being used in a Phase III global post-traumatic stress disorder (PTSD) trial. The Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit research organization is advancing from its MAPP1, the first study carried out in Phase III, to a global confirmatory MAPP2 study to assess the safety and efficacy of MDMA-assisted psychotherapy for patients with PTSD.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025